Immunoprecise Antibodies Ltd Net Income per Employee (IPA), current and historic results, rankings and more, Quarterly Fundamentals - CSIMarket
CSIMarket
 


Immunoprecise Antibodies Ltd   (NASDAQ: IPA)
 

Immunoprecise Antibodies Ltd Net Income per Employee

IPA's Quarterly Results, Trends, Rankings, Statistics
Immunoprecise Antibodies Ltd recorded a cumulative net loss of $-21 million during 12 month ending in the fourth quarter 2024.
The Healthcare sector has seen employees of 72 other companies achieving higher income per employee. While Immunoprecise Antibodies Ltd 's total ranking has deteriorated compared to the previous quarter from 0 to 2650.


What is Income per Employee Ratio?






IPA Net Income per Employee (Apr 30 2024)
IV. Quarter
0
III. Quarter
0
II. Quarter
0
I. Quarter
(Apr 30 2023)
IV. Quarter
Y / Y Net Income Change - - - - -
Net Income per Employee (TTM) $ -16,289 -15,919 -15,919 -15,919 -15,919
IPA's Total Ranking # 2650 # 0 # 0 # 0 # 0
Seq. Net Income Change - - - - -


IPA Net Income per Employee Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 73
Healthcare Sector # 232
Overall Market # 2650

Net Income per Employee Statistics
High Average Low
$ -15,919 $ -16,104 $ -16,289
(Apr 30 2023)   (Apr 30 2024)







Companies with similar Income per Employee for 12 month ending Apr 30 2024, within Healthcare Sector Income per Employee Income 12 month ending Apr 30 2024Number of Employees Apr 30 2024


Date modified: 2026-07-24T14:57:57+00:00




Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.